Vymedic

Clinically-Proven Antiviral Treatment

Company Information

Website:

vymedic.com

Sector:

Biotechnology

Location:

Englewood, CO

Vymedic makes a clinically-proven antiviral treatment that’s superior to what's currently on the market.

Its patented solution, Vymune, is non-strain specific — meaning that, regardless of whether you have the flu, a cold, or any other common virus, it will quickly activate your immune system against the illness. In addition to fighting viruses, this solution also provides immune support for anyone seeking to boost their overall health.

Vymune is sold as a non-prescription melt-away tablet. It starts working immediately, and is safe for the elderly, children, and pregnant women. To prove its safety and efficacy, Vymedic conducted numerous laboratory tests and two clinical studies.

Vymedic aims to reach similar sales as its competitors. Tamiflu, for example, a prescription medication for those with the flu, brought in nearly $1 billion in sales in 2018.

Other immune support products, such as Airborne and Emergen-C, generated more than $100 million in sales in 2018.

Team Background

Cynthia Winning - Founder & CEO
Steve Lehman - Executive Chairman

Co-Investors

Raising
$3 million
Committed
$35.4K (1%)
Current Valuation
$20 million
Min. Investment
$5
Deal Type
Title III
(For all investors)
Offering Type
Equity
Finance History
Notable Investors
Learn more on Netcapital